+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vectura Group plc - logo

Vectura Pharma was established in 1997, and its headquarters are in Chippenham in the U.K. Vectura Group plc researches, develops, and commercializes novel therapeutic products and drug delivery systems for the treatment of airways-related diseases Vectura entered into its first global commercialisation and development agreement with Novartis for NVA237. The company’s marketed products include Ultibro Breezhaler and Seebri Breezhaler for the treatment of chronic obstructive pulmonary disease (COPD).

COPD Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

COPD Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • May 2023
  • 109 Pages
  • Global
From
Vectura Group plc Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis - Product Thumbnail Image

Vectura Group plc Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

  • Company Profile
  • November 2025
  • 50 Pages
From
Vectura Group Plc - Strategic SWOT Analysis Review - Product Thumbnail Image

Vectura Group Plc - Strategic SWOT Analysis Review

  • SWOT Analysis
  • January 2025
  • 25 Pages
From
Vectura Group Limited - Company Profile and SWOT Analysis - Product Thumbnail Image

Vectura Group Limited - Company Profile and SWOT Analysis

  • SWOT Analysis
  • January 2025
  • 41 Pages
From
Loading Indicator